Effects of UCP2 -866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes.

Release time:2016-05-23

Affiliation of Author(s):Central South University

Teaching and Research Group:Xiang-Ya School of Medicine

Journal:Br J Clin Pharmacol.

Place of Publication:british

Funded by:National Natural Science Foundation of China Grants 30572230 and 30873089

Key Words:ADRB3, genetic polymorphism, rosiglitazone, Type 2 diabetes, UCP2

Abstract:Abstract AIMS: The aim of this study was to explore the impact of UCP2 and ADRB3 genetic polymorphisms on the therapeutic efficacy of rosiglitazone in Chinese Type 2 diabetes (T2DM) patients. METHODS: A total of 199 T2DM patients and 155 healthy volunteers were enrolled to identify UCP2 -866 G/A genotypes, and 273 T2DM patients and 166 controls were genotyped for Trp64Arg of ADRB3 by polymerase chain reaction-restriction fragment length polymorphism assay. Nine patients with GG genotype and 27 with GA+AA genotype of UCP2 -866 G/A, 11 with Trp64Trp genotype and 25 with Trp64Arg genotype of

Indexed by:Unit Twenty Basic Research

Document Code:doi: 10.1111/j.1365-2125.2009.03431.x.

Discipline:临床医学

Document Type:J

Volume:68

Issue:1

Page Number:14-22

ISSN No.:doi: 10.1111/j.1365-2125.2009.03431.x.

Translation or Not:no

Date of Publication:2009-03-25

Links to published journals:http://www.ncbi.nlm.nih.gov/pubmed/?term=Effects+of+UCP2+-866+G%2FA+and+ADRB3+Trp64Arg+on+rosiglitazone+response+in+Chinese+patients+with+Type+2+diabetes